COMMUNIQUÉS West-GlobeNewswire

Progenics Pharmaceuticals Completes Enrollment of Phase 2/3 Clinical Trial of PSMA-Targeted PET/CT Imaging Agent PyL™ in Prostate Cancer
26/06/2018
Top-line Data Expected in 4Q2018 NEW YORK, June 26, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and [...]
MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy
26/06/2018
Topline Data Anticipated in Second Half 2020 SOUTH SAN FRANCISCO, Calif., June 26, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine [...]
David King Joins Fluidigm as Vice President, Research and Development, Genomics
26/06/2018
SOUTH SAN FRANCISCO, Calif., June 26, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of David King as Vice President, Research and Development, Genomics. As a member of the [...]
Actinium Pharmaceuticals Announces Dosing of 38th Patient and 25 Percent Enrollment in Iomab-B Pivotal SIERRA Trial
26/06/2018
Iomab-B remains the only targeted conditioning treatment in clinical trials with the potential to increase access to and improve outcomes of bone marrow transplant NEW YORK, June 26, 2018 (GLOBE NEWSWIRE) -- Actinium [...]
Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Ivosidenib in Greater China
26/06/2018
- Agios to Receive $12 Million Upfront Payment and is Eligible to Receive Development, Regulatory, and Sales-Based Milestones and Tiered Royalties - - Collaboration Provides Opportunity for Patients with IDH1m Cancers [...]
PhaseBio Names Michael B. York as Vice President of Corporate Development and Commercial Strategy
26/06/2018
MALVERN, Pa., June 26, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for orphan diseases with an initial focus on [...]
Transplantation Pioneer Dr. Leonard Bailey Co-Founds ADiTx Therapeutics, Inc. to Develop Immune Modulation Treatment for Extending the Life of Transplanted Organs
26/06/2018
Novel ADi technology designed to therapeutically induce immune tolerance to transplanted tissues LOMA LINDA, Calif., June 26, 2018 (GLOBE NEWSWIRE) -- Founders and management comprised of scientific experts and [...]
aTyr Pharma Announces Positive Phase 1 Data for ATYR1923 Therapeutic Candidate
26/06/2018
ATYR1923 Well-Tolerated at all Doses Tested, with No Significant Adverse Events Pharmacokinetic Profile Supports Potential Once-Monthly Dosing SAN DIEGO, June 26, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE [...]
Nu-Med Plus, Inc. Selects s2s Public Relations firm as its Strategic Partner
26/06/2018
The firm specializes in driving investor interest SALT LAKE CITY, June 26, 2018 (GLOBE NEWSWIRE) -- Nu-Med Plus, Inc . (OTCQB:NUMD), a medical device company which investigates and develops nitric oxide applications of [...]
7 Hills Pharma Announces Scientific Advisory Board Formed With Prominent Immuno-Oncology Experts to Help Advance Novel Integrin Activator Program
26/06/2018
HOUSTON, June 26, 2018 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a privately-held immunotherapy company focused on development of novel tumor-targeting cell adhesion agents, announced today the formation of its Scientific [...]
ZEMDRITM (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI)
26/06/2018
― ZEMDRI is a new treatment for patients with cUTI, including pyelonephritis, due to certain Enterobacteriaceae ― ― ZEMDRI is the only once-daily aminoglycoside therapy approved for use in cUTI ― ― ZEMDRI has [...]
Precipio and Nucleai Partner to Develop Artificial Intelligence-Powered Hemepath Solution
26/06/2018
System will support Hematopathologists in accurately identifying abnormalities to ensure diagnostic accuracy NEW HAVEN, Conn., June 26, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO [...]
Arch Therapeutics Provides Skin Sensitization Study Status Update
26/06/2018
Approximately two-thirds of applications in the repeat dosing induction phase are completed; Study remains on track FRAMINGHAM, Mass., June 26, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or [...]
SELLAS Life Sciences Announces Proposed Public Offering of Common Stock
26/06/2018
NEW YORK, June 26, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS” or “the Company”), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range [...]
Helsinn Group and Angelini support Satellite Symposium at MASCC/ISOO 2018 Annual Meeting
26/06/2018
Helsinn Group and Angelini support Satellite Symposium at MASCC/ISOO 2018 Annual Meeting Leading cancer supportive care experts in oncology explore how to provide the best care for patients by discussing the importance [...]
Solon Eiendom ASA : Primary insider notification
26/06/2018
(Oslo, Norway, June 25, 2018) UFI AS has today bought 38.664 shares in Solon Eiendom ASA at a price of NOK 29.9097 per share. Solon Eiendom ASA Board Member Øystein A. Landvik owns 33,34 % of the shares in UFI AS. [...]
Shire plc : Rule 2.9 Announcement
26/06/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 26 June 2018 Shire [...]
IBT plans to start its phase 3 study in the second half of 2018 and contracts CRO
26/06/2018
IBT has previously announced its plan to start the phase 3 study in the first half of 2018. Preparations for the study have taken slightly longer than expected and the Company now plans to initiate the phase 3 study in [...]
FIT Biotech Oy: EHVA clinical trial authorization granted for testing FIT-06 in UK
26/06/2018
FIT Biotech Oy Company release 26.6.2018 at 8:30 AM EET EHVA clinical trial authorization granted for testing FIT-06 in UK FIT Biotech Oy ("Company", FITBIO: FN Finland) today announced that the UK medical authorities [...]

Pages